OncoMed Pharma (OMED) Misses Q1 EPS by 17c

OncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.90), $0.17 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $8.28 million.

For earnings history and earnings-related data on OncoMed Pharma (OMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• SanDisk upgraded at JPMorgan after investor day; shares climb